IL112677A - Pharmaceutical composition for treating autoimmune conditions comprising a therapeutically effective amount of IL-12 or of an IL-12 antagonist - Google Patents

Pharmaceutical composition for treating autoimmune conditions comprising a therapeutically effective amount of IL-12 or of an IL-12 antagonist

Info

Publication number
IL112677A
IL112677A IL11267795A IL11267795A IL112677A IL 112677 A IL112677 A IL 112677A IL 11267795 A IL11267795 A IL 11267795A IL 11267795 A IL11267795 A IL 11267795A IL 112677 A IL112677 A IL 112677A
Authority
IL
Israel
Prior art keywords
autoimmune
antagonist
pharmaceutical composition
effective amount
therapeutically effective
Prior art date
Application number
IL11267795A
Other languages
English (en)
Other versions
IL112677A0 (en
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22791827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL112677(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Inst filed Critical Genetics Inst
Publication of IL112677A0 publication Critical patent/IL112677A0/xx
Publication of IL112677A publication Critical patent/IL112677A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
IL11267795A 1994-03-14 1995-02-16 Pharmaceutical composition for treating autoimmune conditions comprising a therapeutically effective amount of IL-12 or of an IL-12 antagonist IL112677A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21262994A 1994-03-14 1994-03-14

Publications (2)

Publication Number Publication Date
IL112677A0 IL112677A0 (en) 1995-05-26
IL112677A true IL112677A (en) 2000-01-31

Family

ID=22791827

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11267795A IL112677A (en) 1994-03-14 1995-02-16 Pharmaceutical composition for treating autoimmune conditions comprising a therapeutically effective amount of IL-12 or of an IL-12 antagonist

Country Status (14)

Country Link
US (1) US6338848B1 (xx)
EP (4) EP2311484A1 (xx)
JP (1) JP3798426B2 (xx)
AT (1) ATE217533T1 (xx)
AU (1) AU689236B2 (xx)
CA (1) CA2185565C (xx)
DE (1) DE69526728T3 (xx)
DK (1) DK0750509T4 (xx)
ES (1) ES2173953T5 (xx)
IL (1) IL112677A (xx)
PT (1) PT750509E (xx)
TW (1) TW400233B (xx)
WO (1) WO1995024918A1 (xx)
ZA (1) ZA95960B (xx)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6683046B1 (en) 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
US6830751B1 (en) * 1994-03-14 2004-12-14 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of rheumatoid arthritis
US20010055581A1 (en) * 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
DK0936923T3 (da) * 1996-11-15 2004-04-26 Kennedy Inst Of Rheumatology Undertrykkelse af TNFalpha og IL-12 ved terapi
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US7229841B2 (en) 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
KR100764256B1 (ko) * 1998-01-23 2007-10-05 에프. 호프만-라 로슈 아게 인간 인터루킨-12에 대한 항체
US7026456B1 (en) 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
US6410824B1 (en) * 1998-12-09 2002-06-25 Protein Design Labs, Inc. Animal model for psoriasis for the prevention and treatment of psoriasis in humans
CA2362381C (en) 1999-02-10 2009-12-22 Welfide Corporation Amide compounds and medicinal use thereof
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
AU2005200515B2 (en) * 1999-03-25 2006-07-13 AbbVie Deutschland GmbH & Co. KG Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
IL145134A0 (en) * 1999-03-25 2002-06-30 Knoll Gmbh Human antibodies that bind human il-12 and methods for producing
JP4676049B2 (ja) * 1999-07-21 2011-04-27 生化学工業株式会社 Ｉｌ−１２産生抑制剤
US6346247B1 (en) * 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
WO2003083071A2 (en) * 2002-03-26 2003-10-09 Centocor, Inc. Diabetes-related immunoglobulin derived proteins, compositions, methods and uses
JP2008504216A (ja) 2003-12-02 2008-02-14 サイトイミューン サイエンシズ インコーポレイテッド モノクローナル抗体の生成のための方法および組成物
GB0329146D0 (en) * 2003-12-16 2004-01-21 Glaxosmithkline Biolog Sa Vaccine
WO2005085866A1 (en) * 2004-02-27 2005-09-15 Novartis Ag Screening assay for modulators of interaction between interleukin-12 and/or -23 with their receptors
US20060024757A1 (en) * 2004-07-30 2006-02-02 Robert Hussa Detection of oncofetal fibronectin for selection of concepti
NZ583153A (en) 2004-12-21 2011-06-30 Centocor Ortho Biotech Inc Anti-IL-12 antibodies, epitopes, compositions, methods and uses
AU2006283532B2 (en) 2005-08-19 2012-04-26 Abbvie Inc. Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500353A3 (en) 2005-08-19 2012-10-10 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7776331B1 (en) 2007-01-16 2010-08-17 Abbott Laboratories Methods of treating plaque psoriasis
NZ580379A (en) 2007-03-29 2012-10-26 Abbott Lab Crystalline anti-human il-12 antibodies
RU2497545C2 (ru) 2008-03-18 2013-11-10 Эбботт Лэборетриз Способ лечения псориаза (варианты)
CA2722466A1 (en) 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
CA2725666A1 (en) 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
AU2009256250B2 (en) 2008-06-03 2013-05-30 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
NZ590074A (en) 2008-07-08 2012-12-21 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
WO2010039742A2 (en) * 2008-09-30 2010-04-08 Baylor Research Institute Methods to reduce b-helper t cells to treat autoimmune diseases
CN102301235B (zh) * 2008-11-28 2014-11-19 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
IN2012DN02737A (xx) 2009-09-01 2015-09-11 Abbott Lab
SG179135A1 (en) 2009-09-14 2012-05-30 Abbott Lab Methods for treating psoriasis
KR20140015139A (ko) 2009-10-15 2014-02-06 애브비 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
WO2012006500A2 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CA2807014A1 (en) 2010-08-03 2012-02-09 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
TW201211252A (en) 2010-08-26 2012-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2012050829A2 (en) * 2010-09-28 2012-04-19 Neumedicines, Inc. Uses of il-12 and the il-12 receptor positive cell in tissue repair and regeneration
RU2627171C2 (ru) 2010-12-21 2017-08-03 Эббви Инк. Il-1 альфа и бета биспецифические иммуноглобулины с двойными вариабельными доменами и их применение
US20140314710A1 (en) * 2011-05-19 2014-10-23 Rush University Medical Center IL-12 P40 Monomer, Monoclonal Antibody Against P40 Homodimer and the Combination of the Two for Autoimmune Disease Treatment
EP2736530B1 (en) * 2011-07-27 2018-06-06 Neumedicines, Inc Use of il-12 to generate endogenous erythropoietin
UY34558A (es) 2011-12-30 2013-07-31 Abbvie Inc Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
AU2013337775B2 (en) 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3436477A2 (en) 2016-03-29 2019-02-06 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12 and/or -23 antibody
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
EP3793521A4 (en) 2018-05-18 2022-02-23 Janssen Biotech, Inc. SAFE AND EFFECTIVE METHOD OF TREATING LUPUS WITH AN ANTI-IL12/IL23 ANTIBODY
KR20230148273A (ko) 2018-09-24 2023-10-24 얀센 바이오테크 인코포레이티드 항-il12/il23 항체로 궤양성 결장염을 치료하는 안전하고 효과적인 방법
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
EP0790309B1 (en) 1989-12-22 2007-07-25 F. Hoffmann-La Roche Ag Cytotoxic lymphocyte maturation factor 40kD subunit and monoclonal antibodies directed thereto
GB9207732D0 (en) * 1992-04-06 1992-05-27 Isis Innovation Wound repair
DE4315127A1 (de) * 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
US5536657A (en) * 1993-07-19 1996-07-16 Hoffmann-La Roche Inc. Recombinant DNA encoding human receptor for interleukin-12
EP0638644A1 (en) * 1993-07-19 1995-02-15 F. Hoffmann-La Roche Ag Receptors of interleukin-12 and antibodies
US5853721A (en) * 1995-01-31 1998-12-29 Hoffmann-La Roche Inc. Antibody to interleukin-12 receptor
SI9720020B (en) * 1996-02-09 2001-12-31 Basf Ag Human antibodies that bind human TNF alpha
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
EP0998300A1 (en) * 1997-03-18 2000-05-10 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
KR100764256B1 (ko) * 1998-01-23 2007-10-05 에프. 호프만-라 로슈 아게 인간 인터루킨-12에 대한 항체
US8700033B2 (en) 2008-08-22 2014-04-15 International Business Machines Corporation Dynamic access to radio networks
CN102377479B (zh) 2010-08-11 2015-01-21 华为技术有限公司 数据同步方法及系统、光网络单元

Also Published As

Publication number Publication date
EP1179348A2 (en) 2002-02-13
CA2185565C (en) 2009-02-03
WO1995024918A1 (en) 1995-09-21
EP0750509B1 (en) 2002-05-15
CA2185565A1 (en) 1995-09-21
ZA95960B (en) 1995-10-10
DK0750509T3 (da) 2002-07-08
ATE217533T1 (de) 2002-06-15
ES2173953T5 (es) 2007-03-01
EP1179348A3 (en) 2003-12-03
JPH09510444A (ja) 1997-10-21
AU1974995A (en) 1995-10-03
JP3798426B2 (ja) 2006-07-19
DE69526728D1 (de) 2002-06-20
ES2173953T3 (es) 2002-11-01
AU689236B2 (en) 1998-03-26
EP0750509A1 (en) 1997-01-02
EP2201959A3 (en) 2011-03-16
PT750509E (pt) 2002-08-30
DK0750509T4 (da) 2006-10-16
DE69526728T3 (de) 2007-01-04
EP2201959A2 (en) 2010-06-30
IL112677A0 (en) 1995-05-26
EP0750509B2 (en) 2006-06-14
EP2311484A1 (en) 2011-04-20
DE69526728T2 (de) 2002-11-21
TW400233B (en) 2000-08-01
US6338848B1 (en) 2002-01-15

Similar Documents

Publication Publication Date Title
IL112677A (en) Pharmaceutical composition for treating autoimmune conditions comprising a therapeutically effective amount of IL-12 or of an IL-12 antagonist
ATE411029T1 (de) Estrogene als antimitotika
UA37244C2 (uk) Спосіб лікування або профілактики клінічних розладів, виліковних прогестероном, у пацієнтів жіночої статі
DK0754048T3 (da) Behandling af partielt væksthormon-insentivitetssyndrom
AU2840789A (en) Continuous release pharmaceutical compositions
DK0610595T3 (da) Sammensætning af L-DOPA-estere
CA2116559A1 (en) Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
EP0763361A3 (en) Mycobacterium vaccae for treatment of long term autoimmune conditions
JPS55113865A (en) Leveling aging method for age hardening type titanium alloy member
DK399288A (da) Dobbeltstrenget rna-korrektion af abnormiteter i cirkulerende immunkomplekser og monocytfunktion
WO1995013805B1 (en) Use of nitric oxide synthase inhibitors in the treatment of autoimmune diseases
HUT59600A (en) Process for producing pharmaceutical compositions containing 5-methyl-isoxazoe-4-carboxylik-anilides or alpha-/2-hydroxy-ethylidene/-alpha-cyano-acetic-anilides for treating eye-diseases
WO2000067764A3 (en) Improved method for treating mammals with modified mammalian blood
JPS6425717A (en) Method and apparatus for preventing organic nitric acid ester resistance
SE9402370D0 (sv) Use of IGF-I
BE893492A (fr) Procede de preparation d'esters d'acides apovincaminiques, esters ainsi obtenus et compositions pharmaceutiques prepares avec ces esters
OA08298A (fr) Nouvelles N-(aminométhyl-5 oxazolin-2 yl-2) N'-phénylurées, leur méthode de préparation ainsi que leur application thérapeutique.
WO1989005146A3 (en) Method for treatment of dyslipidemia in humans
Shimoda et al. Follow-up Study of Splinting for Pollux Rigidus
Hawkins I recently saw a patient with a most unusual inflammatory arthritis of the knee. Deliberate self-harm was suggested by the general practitioner. How should I evaluate this possibility, and if necessary treat the problem?
Dixon The age of Cimon: the Delian League's foundation and early history
FR2696180B1 (fr) Nouvelles céphalosporines comportant en position 7, un radical benzyloxyimino substitué, leur procédé de préparation et leur application comme médicaments.
Pashchenko The Effect of Strain Rate on Uniform Elongation of a Low Carbon Steel
TH14313EX (th) "โตโคไตรอีนอลและสารประกอบคล้ายโตโคไตรอีนอล และวิธีสำหรับการใช้สารนี้"
IT7926204A0 (it) Glucosammide dell'acido p-isobutilfenilpropionico ad azione terapeutica e procedimento per lasua preparazione.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
HC Change of name of proprietor(s)
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired